Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)

被引：0
|
作者：
De Laurentiis, Michelino [1 ]
Borstnar, Simona [2 ]
Campone, Mario [3 ]
Warner, Ellen [4 ]
Bofill, Javier Salvador [5 ]
Jacot, William [6 ]
Dent, Susan [7 ,17 ]
Martin, Miguel [8 ]
Ring, Alistair [9 ]
Cottu, Paul [10 ]
Lu, Janice [11 ]
Ciruelos, Eva [12 ]
Azim, Hamdy A. [13 ]
Chatterjee, Sanjoy [14 ]
Zhou, Katie [15 ]
Wu, Jiwen [15 ]
Menon-Singh, Lakshmi [15 ]
Zamagni, Claudio [16 ]
机构：
[1] Ist Nazl Tumori IRCCS Fdn Pascale, Dept Breast & Thorac Oncol Director, Div Breast Med Oncol, Naples, Italy
[2] Inst Oncol Ljubljana, Ljubljana, Slovenia
[3] Western Canc Inst, Nantes, France
[4] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[5] Virgen Rocio Univ Hosp, Biomed Inst, Seville, Spain
[6] Montpellier Canc Inst, Montpellier, France
[7] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[8] Univ Complutense, CIBERONC, GEICAM, Gregorio Maranon Gen Univ Hosp, Madrid, Spain
[9] Royal Marsden Hosp NHS Fdn Trust, Sutton, Surrey, England
[10] Curie Inst, Paris, France
[11] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[12] Univ Hosp 12 Octubre, Clara Campal Comprehens Canc Ctr, HM CIOCC, Madrid, Spain
[13] Cairo Univ, Fac Med, Cairo, Egypt
[14] Tata Med Ctr, Kolkata, India
[15] Novartis Pharmaceut, E Hanover, NJ USA
[16] Azienda Ospedaliero Univ Bologna, Bologna, Italy
[17] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2022年 / 191卷 / 01期
关键词：
D O I：
10.1007/s10549-021-06374-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：223 / 224
页数：2
相关论文
共 50 条
  • [1] Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
    De Laurentiis, Michelino
    Borstnar, Simona
    Campone, Mario
    Warner, Ellen
    Bofill, Javier Salvador
    Jacot, William
    Dent, Susan
    Martin, Miguel
    Ring, Alistair
    Cottu, Paul
    Lu, Janice
    Ciruelos, Eva
    Azim, Hamdy A.
    Chatterjee, Sanjoy
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Zamagni, Claudio
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 689 - 699
  • [2] Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
    Michelino De Laurentiis
    Simona Borstnar
    Mario Campone
    Ellen Warner
    Javier Salvador Bofill
    William Jacot
    Susan Dent
    Miguel Martin
    Alistair Ring
    Paul Cottu
    Janice Lu
    Eva Ciruelos
    Hamdy A. Azim
    Sanjoy Chatterjee
    Katie Zhou
    Jiwen Wu
    Lakshmi Menon-Singh
    Claudio Zamagni
    Breast Cancer Research and Treatment, 2021, 189 : 689 - 699
  • [3] Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
    Michelino De Laurentiis
    Simona Borstnar
    Mario Campone
    Ellen Warner
    Javier Salvador Bofill
    William Jacot
    Susan Dent
    Miguel Martin
    Alistair Ring
    Paul Cottu
    Janice Lu
    Eva Ciruelos
    Hamdy A. Azim
    Sanjoy Chatterjee
    Katie Zhou
    Jiwen Wu
    Lakshmi Menon-Singh
    Claudio Zamagni
    Breast Cancer Research and Treatment, 2022, 191 : 223 - 224
  • [4] Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results
    Salvador, J.
    Ciruelos, E. M.
    Jimenez-Rodriguez, B.
    De La Cruz, L.
    Villanueva Vazquez, R.
    De Toro, R.
    Anton, A.
    Moreno, F.
    Alvarez, I.
    Quiroga, V.
    de la Haba, J.
    Gonzalez-Santiago, S.
    Diaz, N.
    Barnadas, A.
    Cantos, B.
    Delgado Mingorance, I.
    Bellet Ezquerra, M.
    Martin, M.
    Martinez, N.
    Vicente, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 119 - +
  • [5] Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2-advanced breast cancer (ABC).
    DeLaurentiis, Michelino
    Borstnar, Simona
    Campone, Mario
    Warner, Ellen
    Bofill, Salvador
    Jacot, William
    Dent, Susan Faye
    Martin, Miguel
    Ring, Alistair E.
    Cottu, Paul H.
    Lu, Janice M.
    Ciruelos, Eva
    Azim, Hamdy A.
    Chatterjee, Sanjoy
    Zhou, Katie
    Wu, Jiwen
    Ankrah, Nii
    Zamagni, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] First-line treatment with ribociclib and letrozole in advanced breast cancer: First interim data from US patients enrolled in the phase 3b CompLEEment-1 clinical trial
    Lu, J.
    Shtivelband, M. I.
    Mitri, Z.
    Chap, L.
    Purkayastha, D.
    Sawhney, A. G.
    Beck, J. T.
    CANCER RESEARCH, 2019, 79 (04)
  • [7] Phase 3b CompLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2-advanced breast cancer: Final results from the UK cohort
    Tuthill, Mark
    Marwaha, Hardeep
    Hartmann, Christoph E. A.
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
    Salvador Bofill, Javier
    Moreno Anton, Fernando
    Rodriguez Sanchez, Cesar Augusto
    Galve Calvo, Elena
    Hernando Melia, Cristina
    Ciruelos Gil, Eva Maria
    Vidal, Maria
    Jimenez-Rodriguez, Begona
    De la Cruz Merino, Luis
    Martinez Janez, Noelia
    Villanueva Vazquez, Rafael
    de Toro Salas, Ruben
    Anton Torres, Antonio
    Alvarez Lopez, Isabel Manuela
    Gavila Gregori, Joaquin
    Quiroga Garcia, Vanesa
    Vicente Rubio, Elena
    de la Haba-Rodriguez, Juan
    Gonzalez-Santiago, Santiago
    Diaz Fernandez, Nieves
    Barnadas Molins, Agusti
    Sanchez de Ibarguen, Blanca Cantos
    Delgado Mingorance, Juan Ignacio
    Bellet Ezquerra, Meritxell
    de Casa, Sonia
    Gimeno, Asuncion
    Martin, Miguel
    BREAST, 2022, 66 : 77 - 84
  • [9] Ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Safety analysis of the phase 3b CompLEEment-1 trial
    Lu, Janice
    Cottu, Paul
    Martin, Miguel
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Ankrah, Nii
    De Laurentiis, Michelino
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib plus letrozole HR+HER2-advanced breast cancer trial
    Califaretti, N.
    Ferrario, C.
    Warner, E.
    Joy, A. A.
    Chia, S. K. L.
    Wu, J.
    Zarate, J. P.
    Menon-Singh, L.
    Leite, R. A.
    Haftchenary, S.
    Perri, S. R.
    Dent, S. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S369 - S370
12345